Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib

Muller, MC, le Coutre, P, Gattermann, N, Scheid, C, Al-Ali, HK, Ottmann, OG, Duyster, J, Blumenstengel, K, Brummendorf, TH, Greil, R, Chalandon, Y, Valent, P, Stegelmann, F, Kneba, M, Schafhausen, P, Saussele, S, Frank, O, Larson, RA, Saglio, G, Hochhaus, A, Lange, T